Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 4479-4484, November 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swaminathan, S.
Right arrow Articles by Bryan, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swaminathan, S.
Right arrow Articles by Bryan, G. T.

Nitroreductase-mediated Metabolic Activation of 2-Amino-4-(5-nitro-2-furyl)thiazole and Binding to Nucleic Acids and Proteins1

Santhanam Swaminathan2, Gerald M. Lower, Jr.3 and George T. Bryan

Division of Clinical Oncology, Department of Human Oncology, Wisconsin Clinical Cancer Center, Madison, Wisconsin 53792

The reductive metabolism of 2-amino-4-(5-nitro-2-furyl)-thiazole (ANFT), a rat urinary bladder and forestomach carcinogen, was examined in vitro using rat liver tissues. ANFT was reduced by rat liver microsomes or cytosol on anaerobic incubation with reduced nicotinamide adenine dinucleotide phosphate. The intermediate(s) produced during the microsomal reduction bound to microsomes and to exogenously added proteins or yeast transfer RNA (tRNA). The binding to tRNA was a function of the concentration of tRNA, microsomes, reduced nicotinamide adenine dinucleotide phosphate, and ANFT. At optimal conditions, up to 10 nmol [2-14C]ANFT metabolite(s) were bound per mg tRNA. Polyacrylamide gel electrophoresis, chromatography, and sensitivity to RNase treatment of the adduct revealed covalent binding between [2-14C]ANFT metabolite(s) and tRNA. Similar covalent binding was observed with proteins. On microsomal reduction of [2-14C]-ANFT, about 7% of the reduced metabolite was bound to a trichloroacetic acid-insoluble fraction, most of which was associated with proteins. Addition of mercaptoethanol, dithiothreitol, reduced glutathione, iodoacetamide, N-ethylmaleimide, or p-chloromercuribenzoate to the incubation mixture significantly reduced the amount of protein binding, suggesting an involvement of sulfhydryl groups in binding. These data demonstrate that reactive intermediate(s) are generated by anaerobic incubation of ANFT with rat liver microsomes. It is suggested that the binding might involve interaction between the nitroso or N-hydroxylamino intermediate(s) and susceptible target sites in yeast tRNA or proteins.

1 Supported in part by Grants CA 11946, CA 14520, and CA 14524 through the National Bladder Cancer Project. Preliminary reports of this work have been made (18, 20).

2 To whom requests for reprints should be addressed, at Department of Human Oncology, Wisconsin Clinical Cancer Center, University of Wisconsin Center for Health Sciences, K4/548 CSC, 600 Highland Avenue, Madison, Wis. 53792.

3 Present address: Center for Human Systems, Institute for Environmental Studies, WARF Building, 610 Walnut Street, Madison, Wis. 53706.

Received 4/12/82. Accepted 8/10/82.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.